Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

"US pulsed field ablation market revenue exceeds $500m in 2024" was originally created and published by Medical Device ...

Most people aren’t aware of the symptoms, especially if they’re otherwise healthy, because they don’t know that AFib can affect anyone!

Adjusted EPS for Q4 was $0.70, surpassing the high-end guidance of $0.66. The FARAPULSE system saw significant adoption, reaching over $1 billion in global revenue in 2024. The WATCHMAN franchise ...

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

The company states: “Boston Scientific (BSX) announced data supporting the use of the FARAPULSE Pulsed Field Ablation System* and the WATCHMAN FLX Left Atrial Appendage Closure Device ...

In late-breaking data presentations, the ADVANTAGE AF trial for the Farapulse PFA system met its primary endpoints, showing a 2.3% safety event rate and 63.5% effectiveness rate in treating persistent ...